The North American Erythropoietic Protoporphyria (EPP) Treatment Market is expected to develop as awareness of rare genetic disorders and access to specialized care continue to improve. The presence of advanced healthcare infrastructure, rare disease research programs, and specialist treatment centers is supporting market development. Growing investments in innovative therapies and improved...